Tirzepatide vs AOD-9604
These two compounds have both been studied for their effects on adipose tissue and body weight, but the pharmacology, the receptor targets, and the depth of the clinical evidence base are markedly different. Tirzepatide is a dual GIP/GLP-1 receptor co-agonist with mature Phase 3 data. AOD-9604 is a modified growth-hormone fragment studied for lipolytic properties with early-phase data only. This page summarises the published distinctions.
Side-by-side comparison
| Property | Compound A | Compound B |
|---|---|---|
| Structural class | Synthetic 39-residue peptide with fatty-acid modification for dual-incretin agonism | Modified C-terminal fragment (amino acids 177-191) of human growth hormone |
| Receptor target | GIP receptor + GLP-1 receptor (dual co-agonist) | Does not bind the GH receptor; proposed lipolytic pathway incompletely characterised |
| Clinical evidence base | Mature Phase 3 programs (SURPASS for T2DM, SURMOUNT for obesity) | Early-phase clinical and preclinical studies |
| Published body-weight reduction | Approximately 20% at 15 mg weekly over 72 weeks (SURMOUNT-1) | Modest weight loss reported in rodent models; human data limited |
| Regulatory status | FDA approved for type 2 diabetes and obesity under separate brand names | Not approved as a therapeutic by the FDA or Health Canada |
| Common research administration route | Subcutaneous injection | Subcutaneous injection |
| Ronin catalog vial size | 10 mg lyophilised | 5 mg lyophilised |
How they differ in mechanism
Tirzepatide activates both the GIP receptor and the GLP-1 receptor as a dual co-agonist with biased and imbalanced potency. The GLP-1 arm drives glucose-dependent insulin secretion, glucagon suppression, gastric emptying delay, and central appetite reduction. The GIP arm contributes additional secretagogue and adipose-tissue effects. The combined receptor engagement produces the body-weight and glycaemic outcomes characterised across the SURPASS and SURMOUNT programs.
AOD-9604 is a synthetic fragment corresponding to amino acids 177-191 of the human growth hormone C-terminal region with a tyrosine substitution. Published preclinical work reports lipolytic and fat-oxidation activity without the growth-promoting or diabetogenic effects of intact growth hormone. The fragment does not engage the growth hormone receptor. The precise signalling pathway has not been fully resolved in the published mechanistic literature.
The difference in evidence depth is substantial. Tirzepatide has randomised controlled trials with hard clinical endpoints, receptor-pharmacology characterisation at the molecular level, and FDA approval. AOD-9604 has rodent pharmacology and limited early-phase human studies. Any comparison between the two in a research context must account for this asymmetry.
How research has examined each
The tirzepatide clinical literature includes five SURPASS trials in type 2 diabetes and the SURMOUNT program in obesity. Published secondary analyses cover liver-fat reduction, body composition, heart failure with preserved ejection fraction, and obstructive sleep apnea. Receptor-pharmacology work has characterised the imbalanced and biased dual-agonism profile at the molecular level.
The AOD-9604 literature centres on rodent adipose-tissue studies by Heffernan and colleagues in the early 2000s, demonstrating fat oxidation and weight loss in obese mice. A limited human pharmacology literature exists. More recent work by Kwon and colleagues has examined AOD-9604 in an intra-articular injection context for osteoarthritis in a rabbit model, suggesting potential applications outside the metabolic space.
The two literatures do not meaningfully overlap. Tirzepatide is discussed within the incretin-pharmacology and obesity-clinical-trial communities. AOD-9604 is discussed within the growth-hormone-fragment and experimental-metabolic-peptide communities. A researcher reading both is reading two separate bodies of work with different lead authors, different journals, and different evidence standards.
Stacking considerations in research contexts
Combined administration of tirzepatide and AOD-9604 is not described in the published research. There is no receptor-level overlap (dual-incretin agonism versus an incompletely characterised lipolytic pathway), so no direct pharmacological collision is anticipated, but the absence of published combined-protocol data means any stacking protocol would be investigator-designed. Both compounds are sold as separate vials in the Ronin catalog (tirzepatide at 10 mg, AOD-9604 at 5 mg).
Sourcing both at Ronin
Both compounds in the Ronin catalog ship as lyophilised peptide in glass vials, capped and crimped, with certificate-of-analysis documentation (mass spec + HPLC purity) on the lab-results page. The tirzepatide vial page ships at 10 mg per vial. The AOD-9604 vial page ships at 5 mg per vial. Both carry per-compound spec sheets, reconstitution math, and storage guidance. Both are sold strictly as research-grade reagents for laboratory and bench-research applications.
Frequently asked research questions
Are tirzepatide and AOD-9604 related pharmacologically?
No. Tirzepatide is a dual GIP/GLP-1 receptor co-agonist. AOD-9604 is a modified C-terminal fragment of human growth hormone investigated for lipolytic activity. They share no receptor targets or signalling pathways.
How does the clinical evidence compare?
Tirzepatide has a mature Phase 3 program with FDA approval for type 2 diabetes and obesity. AOD-9604 has early-phase human data and preclinical rodent studies without large-scale confirmation.
Can they be co-administered in research?
Combined-administration protocols have not been published. The receptors do not overlap, but there is no precedent for the combination in the indexed literature.
Do they share reconstitution practice?
Yes. Both are lyophilised peptides in glass vials, reconstituted in bacteriostatic water, and stored refrigerated at 2-8 °C protected from light.
Are either approved for human therapeutic use under Ronin?
No. Tirzepatide is FDA-approved under separate brand names. AOD-9604 is not approved as a therapeutic. Both Ronin vials are research-grade reagents for laboratory use only.
References
- Heffernan MA et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. International Journal of Obesity, 2001. [PMID 11673763]
- Wilding J. AOD-9604 Metabolic. Current Opinion in Investigational Drugs, 2004. [PMID 15134286]
- Willard FS et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight, 2020. [PMID 32730231]
- Frias JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). New England Journal of Medicine, 2021. [PMID 34170647]
- Kwon DR et al. Effect of intra-articular injection of AOD9604 with or without hyaluronic acid in rabbit osteoarthritis model. Annals of Clinical and Laboratory Science, 2015. [PMID 26275694]
Comparison pages describe research-context use of the compared compounds. They do not constitute medical, veterinary, or clinical advice. Every compound in the Ronin catalog is sold strictly for laboratory and research use only.